Copyright©IBMI & RBMP. To share this article, please indicate the source with a link back to it.
According to MOPS Taiwan’s release of salary information on 30 June, 2022, which unveiled the average salary of non-managerial employees in the biomedical sector, there were 15 companies with the pay per annum over and well over 1M in Taiwan Dollar (TWD) and the other 14 with a double-digit salary growth.
Remuneration below refers to Taiwan Dollar. (As of 6 July, USD:TWD / 1:29.82)
Salary of public companies shrank 0.2% in average: As per MOPS, the average pay in 2021 was 728K. Amongst listees, 64.3% presented growth.
Of this cohort, the forerunners were Lotus Pharma (1.03M), CHC Healthcare (1.02M), Formosa Laboratories (965K), Chunghwa Chemical Synthesis & Biotech (963K) and Excelsior Medical (893K).
Salary of OTC companies up by 1.6% in average: The average pay in 2021 was 771K. Amongst OTCs, 61.8% presented growth.
Of this cohort, the forerunners were PharmaEngine (2.03M), Medeon (1.51M), Foresee Pharmaceuticals (1.26M), TTY Biopharm (1.17M) and PharmaEssentia (1.15M).
15 Companies with Salary Over 1 Million
(1 Million, TWD)
|3||OTC||Foresee Pharmaceuticals (逸達)||1.26|
|4||OTC||TTY Biopharm (東洋)||1.17|
|7||OTC||Senhwa Bioscience (生華科)||1.12|
|8||OTC||Medigen Vaccine Biologics (高端疫苗)||1.08|
|9||OTC||TSH Biopharm (東生華)||1.07|
|10||OTC||OBI Pharma (浩鼎)||1.06|
|11||OTC||Orient EuroPharma (友華)||1.04|
|12||Listed||Lotus Pharma (美時)||1.03|
|14||Listed||CHC Healthcare (承業醫)||1.02|
|15||OTC||Medigen Biotechnology (基亞)||1.01|
And there were 14 companies, inclusive of listed and OTC, that came with a double-digit growth in salary: Top three went to Medeon, Intech Biopharm and Formosa Laboratories.
14 Companies with A Double-Digital Growth in Salary
|Status||Company||Annual Growth Rate|
|2||OTC||Intech Biopharm (益得)||22.2%|
|3||Listed||Formosa Laboratories (台耀)||20.3%|
|4||OTC||Medigen Vaccine Biologics (高端疫苗)||19.1%|
|5||OTC||Crystalvue Medical (明達醫)||16.3%|
|6||OTC||Dr. Wu (達爾膚)||15.3%|
|7||OTC||St.Shine Technology (精華)||14.9%|
|8||OTC||Foresee Pharmaceuticals (逸達)||14.6%|
|9||OTC||Xingbao International (星寶國際)||13%|
|10||OTC||GGA Corp (創源生技)||12.1%|
|12||OTC||Medigen Biotechnology (基亞)||10.8%|
|14||OTC||Polylite Taiwan (寶利徠)||10.1%|
Amongst 28 listees and 89 OTCs, excluding one OTC without pay information, the growth rate in terms of salary and EPS below showed that 36.2% of companies moved towards the upper right quadrant, 26.7% towards the lower right (salary+, eps-), 11.2% towards the upper left (eps+, salary-) and 25.9% fell into the lower left where both indicators deteriorated.
The biomedical sector in 2021 ranked 25 amongst 28 industries trading publicly and 16 amongst 27 trading in Taipei’s OTC market. Both rankings, compared to 2020, moved downwards.
Source: MOPS; compiled by IBMI & RBMP.